A carregar...
Combination of celecoxib (Celebrex(®)) and CD19 CAR-redirected CTL immunotherapy for the treatment of B-cell non-Hodgkin’s lymphomas
The nonsteroidal anti-inflammatory drug (NSAID) Celecoxib (Celebrex(®)) received Food and Drug Administration (FDA) approval in 1998 for treatment of osteoarthritis and rheumatoid arthritis, and in recent years, its use has been extended to various types of malignancies, such as breast, colon, and u...
Na minha lista:
| Publicado no: | Am J Clin Exp Immunol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
e-Century Publishing Corporation
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5545683/ https://ncbi.nlm.nih.gov/pubmed/28804691 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|